Quality of life assessment in patients with HNF1A-MODY and GCK-MODY.

Magdalena SzopaBartlomiej MatejkoDamian UcieklakAgata UchmanJerzy HohendorffSandra MrozińskaWojciech GłodzikBarbara ZapałaTeresa PłatekIwona SoleckaCyrus M SaniMaciej T Małecki

Published in: Endocrine (2018)

MODY has a smaller negative impact on QoL compared to T1DM. Mode of treatment further stratifies QoL decline for HNF1A-MODY subjects.

Keyphrases

nuclear factor
type diabetes
immune response
combination therapy
skeletal muscle
insulin resistance